Division of Angiology and Hemostasis, Geneva University Hospital and Faculty of Medicine, Geneva, Switzerland.
Vasa. 2024 May;53(3):185-192. doi: 10.1024/0301-1526/a001119. Epub 2024 Mar 28.
Isolated distal deep vein thrombosis (DVT) represents up to 50% of all lower limb DVT in ultrasound series and is a frequent medical condition, which management is not well established. Data arising from registries and non-randomized studies suggest that most distal DVTs do not extend to the proximal veins and have an uneventful follow-up when left untreated. This data had some impact on international recommendations like the American College of Chest Physicians (ACCP), whose last version stated that ultrasound surveillance might be an option for selected low-risk patients. However, robust data arising from randomized studies are scarce. Indeed, only seven randomized trials assessing the need for anticoagulation for calf DVT have been published. Many of these trials had an open-label design and were affected by methodological limitations. When considering randomized placebo-controlled trials, one included low-risk patients and was hampered by a limited statistical power (CACTUS study). Nevertheless, data from this trial tend to confirm that the use of therapeutic anticoagulation in low-risk patients with symptomatic calf DVT is not superior to placebo in reducing VTE but is associated with a higher risk of bleeding. A second randomized placebo-controlled trial did not assess the necessity of anticoagulant treatment but rather the long-term risk of recurrence and compared 6 weeks versus 12 weeks of treatment with rivaroxaban (RIDTS study). Finally, the last available randomized trial compared a 3-month versus a 12-month edoxaban treatment in patients with cancer and mainly asymptomatic distal DVT, detected by systematic compression ultrasonography. Overall, available data suggest that the use of therapeutic anticoagulation in low-risk patients with symptomatic calf DVT is not superior to placebo in reducing VTE. High risk patients (previous VTE, active cancer, inpatients) might benefit from a course of anticoagulant treatment. However, the optimal anticoagulant intensity and duration are uncertain and further studies are needed.
孤立性远端深静脉血栓形成(DVT)占超声系列中所有下肢 DVT 的 50%左右,是一种常见的医疗状况,其管理尚未得到很好的确立。来自登记处和非随机研究的数据表明,大多数远端 DVT 不会延伸到近端静脉,如果不治疗,其后续情况通常良好。这些数据对国际建议产生了一定影响,例如美国胸科医师学会(ACCP),其最新版本指出,超声监测可能是选择低风险患者的一种选择。然而,来自随机研究的可靠数据仍然很少。实际上,只有七项评估抗凝治疗小腿 DVT 必要性的随机试验已经发表。这些试验中的许多都采用了开放标签设计,并且受到方法学限制的影响。在考虑随机安慰剂对照试验时,其中一项试验纳入了低风险患者,但由于统计效力有限而受到阻碍(CACTUS 研究)。尽管如此,该试验的数据倾向于证实,在有症状的小腿 DVT 的低风险患者中使用治疗性抗凝治疗并不优于安慰剂,可降低 VTE 但与更高的出血风险相关。第二项随机安慰剂对照试验没有评估抗凝治疗的必要性,而是比较了利伐沙班治疗 6 周与 12 周(RIDTS 研究)的长期复发风险。最后,最后一项可用的随机试验比较了依度沙班治疗 3 个月与 12 个月在患有癌症和主要无症状远端 DVT 的患者中的效果,这些 DVT 是通过系统压缩超声检测到的。总体而言,现有数据表明,在有症状的小腿 DVT 的低风险患者中使用治疗性抗凝治疗并不优于安慰剂,可降低 VTE。高危患者(既往 VTE、活动性癌症、住院患者)可能受益于抗凝治疗。然而,最佳抗凝强度和持续时间尚不确定,需要进一步研究。